Avlayah savings card: as little as $0 a dose with commercial insurance

Avlayah is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Avlayah is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameAvlayah

Authorized generictividenofusp alfa-eknm

Regular generictividenofusp alfa-eknm

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Avlayah?

The original

–

Brand nameThe maker’s card

Denali Patient Services Copay Program

Savings card from Denali Therapeutics

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a dose

Or call 1-844-365-4365.

In the maker’s words

“AVLAYAH patient may pay as little as $0 out-of-pocket for each dose of AVLAYAH.”

From the maker’s offer on avlayah.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Avlayah itself, from the same company, sold without the brand name, and usually for less. For now Avlayah is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Avlayah is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Brain and nerve symptoms of Hunter syndrome (MPS II)

What the FDA label says

AVLAYAH is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.

This indication is approved under accelerated approval based on reduction of cerebrospinal fluid heparan sulfate observed in patients treated with AVLAYAH. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Limitations of Use

AVLAYAH is not recommended for use in combination with other enzyme replacement therapies.

Source: the FDA label for Avlayah (Denali Therapeutics Inc.), March 20, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/avlayah/